Ångström AI vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Angstrom AI is a medical imaging AI company applying computer vision to analyze radiology scans and pathology slides to assist radiologists and pathologists with diagnosis. HQ: San Francisco.
About
Angstrom AI is a medical AI company developing computer vision models for clinical imaging analysis — applying deep learning to radiology images (X-rays, CT scans, MRIs) and digital pathology slides to assist physicians in detection and diagnosis. The company's AI models are trained to identify specific findings (nodules, lesions, abnormalities) in medical images, providing radiologists and pathologists with highlighted regions of interest and preliminary analysis that supports their diagnostic workflow. AI-assisted reading reduces the time required per scan, improves consistency, and provides a quality check layer for findings that could otherwise be missed under time pressure.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.